Lantern Pharma, Inc. (LTRN)
3.035
+0.04
(+1.17%)
USD |
NASDAQ |
May 19, 13:12
Lantern Pharma Research and Development Expense (Quarterly) : 1.725M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioVie, Inc. | 3.177M |
| Vertex Pharmaceuticals, Inc. | 961.60M |
| Spero Therapeutics, Inc. | 2.909M |
| Replimune Group, Inc. | 52.87M |
| Acurx Pharmaceuticals, Inc. | 0.3415M |